Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Limited rollout of its cardioplagia safety system (CSS) for use during stopped-heart coronary artery bypass surgery commences following 510(k) clearance May 4, the firm reports. The device "controls potassium flow level and dilution, monitors flow pressure and guards against air in the line" after blood flow through the aorta is stopped and potassium is delivered to arrest the heartbeat, Medtronic says in a May 12 release. The CSS features reduce the incidence of accidental vessel rupture due to over pressurization, the firm claims...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.